Overview of Hyperuricaemia and Gout

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|11|32|4117-4124

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.11, Iss.32, 2005-12, pp. : 4117-4124

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Testosterone: First report of gout and hyperuricaemia: case report

By  

Reactions Weekly, Vol. 1, Iss. 1229, 2008-01 ,pp. : 28-28

Adis International

Access to resources Recommend Favorite

Febuxostat for the Management of Hyperuricaemia in Patients with Gout: A NICE Single Technology Appraisal

By Stevenson Matt   Pandor Abdullah  

PharmacoEconomics, Vol. 29, Iss. 2, 2011-02 ,pp. : 133-140

Adis International

Access to resources Recommend Favorite

Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout

By Schumacher Jr   H Ralph  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 7, 2005-07 ,pp. : 893-903

Informa Healthcare

Access to resources Recommend Favorite

Overview of the Management of Acute Gout and the Role of Adrenocorticotropic Hormone

By Schlesinger Naomi  

Drugs, Vol. 68, Iss. 4, 2008-01 ,pp. : 407-415

Adis International

Access to resources Recommend Favorite

Dietary Factors and Hyperuricaemia

By  

Current Pharmaceutical Design, Vol. 11, Iss. 32, 2005-12 ,pp. : 4133-4138

Bentham Science Publishers

Access to resources Recommend Favorite